Multiple Genetic Alterations within the PI3K Pathway Are Responsible for AKT Activation in Patients with Ovarian Carcinoma

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  De Marco, Carmela ^a,b   Rinaldo, Nicola ^b   Bruni, Paola ^c   Malzoni, Carmine ^c   Zullo, Fulvio ^a   Fabiani, Fernanda ^a   Losito, Simona ^d   Scrima, Marianna ^a,b   Marino, Federica Zito ^d   Franco, Renato ^d   Quintiero, Alfina ^a   Agosti, Valter ^a   Viglietto, Giuseppe ^a,b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Grande Ospedale Metropolitano   (Italy)

^c Casa di Cura Malzoni Villa dei Platani   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP A1C PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN FOS; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110 ALPHA; S6 KINASE; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG;

ADULT; AGED; AKT1 GENE; AKT2 GENE; ARTICLE; CANCER PATIENT; CARCINOGENESIS; COHORT ANALYSIS; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME MECHANISM; ETHNIC GROUP; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; ITALIAN; KRAS GENE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PROTEIN DEPLETION; PROTEIN EXPRESSION; SAMPLE; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84873595925     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055362     Document Type: Article

References (71)

1. Fishman DA, Bozorgi K (2001) The scientific basis of early detection of epithelial ovarian cancer: the national ovarian cancer early detection program (NOCEDP). In Cancer Treatment and Research: Ovarian Cancer. In: Stack MS, Fishman DA editors. Boston: Kluwer Academic Publishers. 3-28.
2. Fader AN, Rose PG, (2007) Role of surgery in ovarian carcinoma. J Clin Oncol 25: 2873-2883.
3. Levanon K, Crum C, Drapkin R, (2008) New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26: 5284-5293.
4. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC, (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22: 255-288.
5. Feeley KM, Wells M, (2001) Precursor lesions of ovarian epithelial malignancy. Histopathology 38: 87-95.
6. Bowtell DD, (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10: 803-808.
7. Barda G, Menczer J, Chetrit A, Lubin F, Beck D, et al. (2004) Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study. Am J Obstet Gynecol 190: 1039-1045.
8. Natioanl Institute of Health website. National Library of Medicine. Ovarian Cancer. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/000889.htm. Accessed 2012 Mar 15.
9. National Cancer Institute website. Cancer Topics: Ovarian Cancer. Available at: http://www. cancergov/cancertopics/types/ovarian. Accessed 2012 Mar 19.
10. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics. CA Cancer J Clin 60: 277-300.
11. The Cancer Genome Atlas Research Network, (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
12. Bast RC Jr, Hennessy B, Mills GB, (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: 415-428.
13. Landen CN Jr, Birrer MJ, Sood AK, (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26: 995-1005.
14. Bast RC Jr, Mills GB, (2010) Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 28: 3545-3548.
15. Cantley LC, (2002) The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
16. Vivanco I, Sawyers CL, (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
17. Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, et al. (2000) Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19: 2324-2330.
18. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, et al. (2004) AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23: 5853-5857.
19. Cristiano BE, Chan JC, Hannan KM, Lundie NA, Marmy-Conus NJ, et al. (2006) A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. Cancer Res 66: 11718-11725.
20. Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, et al. (2001) Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 158: 2097-2106.
21. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, et al. (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21: 99-102.
22. Willner J, Wurz K, Allison KH, Galic V, Garcia RL, et al. (2007) Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol 38: 607-613.
23. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, et al. (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64: 7678-7681.
24. Zhang L, Huang J, Yang N, Greshock J, Liang S, et al. (2007) Integrative genomic analysis of phosphatidylinositol 3′-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res 13: 5314-5321.
25. Woenckhaus J, Steger K, Sturm K, Münstedt K, Franke FE, et al. (2007) Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer. Virchows Arch 450: 387-395.
26. Russel P (1995) Surface epithelial-stromal tumors of the ovary. In: Kurman RJ editor. Blaustein's Pathology of the Female Genital Tract. New York: Springer-Verlag. 705-782.
27. Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, et al. (2001) Tissue microarray: a new technology for amplification of tissue resources. Cancer J 7: 24-31.
28. Scrima M, De Marco C, Fabiani F, Franco R, Pirozzi G, et al. (2012) Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase. PLoS One 7: e30427.
29. Rychahou PG, Kang J, Gulhati P, Doan HQ, Chen LA, et al. (2008) Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci U S A 105: 20315-20320.
30. Aziz SA, Davies M, Pick E, Zito C, Jilaveanu L, et al. (2009) Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Cancer Res 15: 3029-3036.
31. Carvalho S, Milanezi F, Costa JL, Amendoeira I, Schmitt F, (2010) PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer. Virchows Arch 456: 235-243.
32. Liu JF, Zhou XK, Chen JH, Yi G, Chen HG, et al. (2010) Up-regulation of PIK3CA promotes metastasis in gastric carcinoma. World J Gastroenterol 16: 4986-4991.
33. Lin Y, Jiang X, Shen Y, Li M, Ma H, et al. (2009) Frequent mutations and amplifications of the PIK3CA gene in pituitary tumours. Endocr Relat Cancer 16: 301-310.
34. No JH, Jeon YT, Park IA, Kim YB, Kim JW, et al. (2011) Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer. Gynecol Oncol 121: 8-12.
35. Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, et al. (2009) mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary. Clin Cancer Res 15: 5404-5413.
36. Trinh XB, Tjalma WAA, Vermeulen PB, Van den Eynden G, Van der Auwera I, et al. (2009) The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. British Journal of Cancer 100: 971-978.
37. Lee SH, Kim HS, Park WS, Kim SY, Lee KY, et al. (2002) Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS 110: 587-92.
38. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, et al. (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27: 2622-2629.
39. Wang G, Kang C, Pu P, (2010) Increased expression of Akt2 and activity of PI3K and cell proliferation with the ascending of tumor grade of human gliomas. Clin Neurol Neurosurg 112: 324-327.
40. Rojo F, Najera L, Lirola J, Jimenez J, Guzman M, et al. (2007) 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 13: 81-89.
41. Kirkegaard T, Witton CJ, Edwards J, Nielsen KV, Jensen LB, et al. (2010) Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH. Histopathology 56: 203-211.
42. Abubaker J, Bavi P, Al-Haqawi W, Jehan Z, Munkarah A, et al. (2009) PIK3CA alterations in Middle Eastern ovarian cancers. Mol Cancer 8: 51-62.
43. Sambrook J, Fritsch EF, Maniatis T (1992) Molecular Cloning: A Laboratory Manual 2. New York: Cold Spring Harbor Laboratory Press.
44. Chomczynski P, Sacchi N, (1987) Single-step method of RNA from isolated by acid guanidinium thiocyanate-phenol-chlorophorm extraction. Anal Biochem 162: 156-159.
45. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Method Methods 25: 402-408.
46. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, et al. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561-573.
47. Mayr D, Hirschmann A, Löhrs U, Diebold J, (2006) KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 103: 883-887.
48. Auner V, Kriegshäuser G, Tong D, Horvat R, Reinthaller A, et al. (2009) KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 9: 111.
49. Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM, (1991) K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 139: 777-785.
50. Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, et al. (2003) Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 90: 378-381.
51. Singer G, Oldt R III, Cohen Y, Wang BG, Sidransky D, et al. (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95: 484-486.
52. de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, et al. (2008) The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer 99: 341-349.
53. Manning BD, Cantley LC, (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
54. Guertin DA, Sabatini DM, (2007) Defining the role of mTOR in Cancer. Cancer Cell 12: 9-22.
55. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, et al. (2009) AKT-Indipendent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer. Cancer Cell 16: 21-32.
56. Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, et al. (2005) Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol 124: 392-401.
57. Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, et al. (2001) The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61: 7426-7429.
58. Kim MS, Jeong EG, Yoo NJ, Lee SH, (2008) Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 98: 1533-1535.
59. Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, et al. (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58: 2095-2097.
60. Sato T, Saito H, Morita R, Koi S, Lee JH, et al. (1991) Allelotype of human ovarian cancer. Cancer Res 51: 5118-5122.
61. Marks JL, McLellan MD, Zakowski MF, Lash AE, Kasai Y, et al. (2007) Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One 2: e426.
62. Kawano O, Sasaki H, Okuda K, Yukiue H, Yokoyama T, et al. (2007) PIK3CA gene amplification in Japanese non-small cell lung cancer. Lung Cancer 58: 159-160.
63. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, et al. (2008) PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 68: 6913-6921.
64. Oda K, Stokoe D, Taketani Y, McCormick F, (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65: 10669-10673.
65. Stemke-Hale K, Gonzales-Angulo AM, Lluch A, Neve RM, Kuo WL, et al. (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-6091.
66. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB, (2002) Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62: 1087-1092.
67. Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH, (2006) Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal 18: 2262-2271.
68. Zhang X, Deng HX, Zhao X, Su D, Chen XC, et al. (2009) RNA interference-mediated silencing of the phosphatidylinositol 3-kinase catalytic subunit attenuates growth of human ovarian cancer cells in vitroand in vivo. Oncology 77: 22-32.
69. Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Ivetac I, et al. (2012) An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest 122: 553-557.
70. Amodio N, Scrima M, Palaia L, Salman AN, Quintiero A, et al. (2010) Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am J Pathol 177: 2622-2634.
71. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, et al. (2008) MicroRNA Expression Profiling in Human Ovarian Cancer: miR-214 Induces Cell Survival and Cisplatin Resistance by Targeting PTEN. Cancer Res 68: 425-433.